France has moved the reimbursement threat from price to presence. A smaller price-cut envelope eases the annual squeeze, but an established brand’s place on the reimbursement list can now be questioned once a better treatment launches. For incumbents, a competitor’s arrival in France becomes a reimbursement event as well as a commercial one.

• Established brands: the review trigger now sits with competitors. HAS will be able to give an opinion on keeping a medicine reimbursed in light of newer, more effective options. Brands with a stronger entrant on the horizon should have comparative evidence and a price position ready before the review opens.
• New entrants: the golden rule is a launch argument. The rule ties a newcomer’s arrival to a review of what it replaces, and the government links the smaller price cuts to supporting particularly effective new medicines. A dossier that shows superiority over a named incumbent now works twice, for the entrant’s price and against the incumbent’s listing.
• Signposts: how the article defines the trigger, and what Parliament does with it. The review criteria, the timetable and any route to contest an HAS opinion will decide whether this reaches a handful of products or the whole list. With ONDAM growth capped at 2.0% and the deficit target cut from €21.8 billion to €12.7 billion, any amendment that softens the rule will need savings found elsewhere.